Changes in Hong Kong stocks | Xuanzhu Bio-B (02575) surged more than 40% in the afternoon, and revenue surged nearly threefold year-on-year in the first half of the year. This year was the first year of Xuan Yuening's full volume

The Zhitong Finance App learned that Xuanzhu Bio-B (02575) soared more than 40% in the afternoon. As of press release, it rose 38.22% to HK$13.0, with a turnover of HK$43.6583 million.

According to the news, Xuanzhu Biotech achieved revenue of 69.4 million yuan in the first half of the year, an increase of 288.1% over the previous year, mainly driven by the launch of new products and inclusion in the national basic medical insurance drug catalogue. According to reports, Xuan Yuening added first-line indications and was included in medical insurance in March 2026, and 2026 was the first year of full dosage; with a high intracranial objective remission rate of 91.7% and a low discontinuation rate of 1.5%, Xuan Feining faced competition from three generations of drugs in the ALK-positive NSCLC field, with obvious differentiation advantages.

Northeast Securities previously released a research report stating that the company has built a full-chain platform for small molecules, large molecules, and small nucleic acids. The core asset under development, XZP-7797, has initiated phase I clinical trials. It is expected that data will be read out in Q4 2026, with reference to similar asset transactions, and has high potential for overseas licensing. The company's BD strategy is pragmatic. In April 2026, it reached a license with Boston Oncology in 21 countries in the Middle East and North Africa. The potential milestone exceeds 100 million US dollars, verifying international monetization capabilities. In the future, it is not ruled out that higher volume transactions will be reached on early pipelines in mainstream European and American markets.